According to Evotec, the research collaboration – which combines Evotec's drug discovery and preclinical development platforms with Almirall's dermatology disease expertise – is expected to deliver highly potent and durable treatments for diseases such as psoriasis and atopic dermatitis.
Almirall is a skin-health focused global pharmaceutical company. Per the agreement terms, Evotec will receive research funding and may be eligible to receive discovery, preclinical, clinical, and sales milestone payments, in addition to tiered royalties.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said the goal is to “jointly address highly validated targets via a new approach that has the potential to deliver superior first-in-class drug products.”
“This platform enables disruption of cell signaling via a new approach that has been identified and developed by Evotec scientists in Toulouse and is expected to deliver many more drug discovery opportunities,” he said in the press release.